BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 23469895)

  • 1. BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic infiltration is present.
    Marotta V; Guerra A; Zatelli MC; Uberti ED; Di Stasi V; Faggiano A; Colao A; Vitale M
    Clin Endocrinol (Oxf); 2013 Nov; 79(5):733-8. PubMed ID: 23469895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined effect of Hashimoto's thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer.
    Kim SJ; Myong JP; Jee HG; Chai YJ; Choi JY; Min HS; Lee KE; Youn YK
    Head Neck; 2016 Jan; 38(1):95-101. PubMed ID: 25213729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Endocr Relat Cancer; 2016 Jan; 23(1):27-34. PubMed ID: 26598713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
    Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
    Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF(V600E) assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto's thyroiditis is a reliable assay.
    Guerra A; Di Stasi V; Zeppa P; Faggiano A; Marotta V; Vitale M
    Endocrine; 2014 Mar; 45(2):249-55. PubMed ID: 23775008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation Between the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated with Hashimoto's Thyroiditis, BRAF V600E Gene Mutation, and RET Gene Rearrangement.
    Xie M; Xu ZX; Dai M; Zhu YY
    J Coll Physicians Surg Pak; 2024 Apr; 34(4):445-450. PubMed ID: 38576288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
    Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
    Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does papillary thyroid carcinoma have a better prognosis with or without Hashimoto thyroiditis?
    Kwak HY; Chae BJ; Eom YH; Hong YR; Seo JB; Lee SH; Song BJ; Jung SS; Bae JS
    Int J Clin Oncol; 2015 Jun; 20(3):463-73. PubMed ID: 25312294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential diagnosis of diffuse sclerotic thyroid papillary carcinoma and Hashimoto's thyroiditis using fine-needle aspiration cytology, BRAF
    Wang X; Xu F; Gao J; Agyekum EA; Sun H; Zhang G; Li X; Xiang H; Hu S; Qian X
    J Clin Ultrasound; 2022 Sep; 50(7):942-950. PubMed ID: 35779272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential relationship between Hashimoto's thyroiditis and BRAF(V600E) mutation status in papillary thyroid cancer.
    Zeng RC; Jin LP; Chen ED; Dong SY; Cai YF; Huang GL; Li Q; Jin C; Zhang XH; Wang OC
    Head Neck; 2016 Apr; 38 Suppl 1():E1019-25. PubMed ID: 26041461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and Impact of BRAF mutation in patients with concomitant papillary thyroid carcinoma and Hashimoto's thyroiditis: a systematic review with meta-analysis.
    Janicki L; Patel A; Jendrzejewski J; Hellmann A
    Front Endocrinol (Lausanne); 2023; 14():1273498. PubMed ID: 38047109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
    Guerra A; Zeppa P; Bifulco M; Vitale M
    Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
    Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between BRAF (V600E) mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series.
    Pessôa-Pereira D; Medeiros MFDS; Lima VMS; Silva JCD; Cerqueira TLO; Silva ICD; Fonseca LE; Sampaio LJL; Lima CRA; Ramos HE
    Arch Endocrinol Metab; 2019; 63(2):97-106. PubMed ID: 30916170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis.
    Kim SK; Song KH; Lim SD; Lim YC; Yoo YB; Kim JS; Hwang TS
    Thyroid; 2009 Feb; 19(2):137-41. PubMed ID: 19014278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between BRAF
    Shangguan R; Hu YP; Huang J; Yang SJ; Ye L; Lin RX; Zhu J; Zhang TL; Ying L; Li P
    Acad Radiol; 2019 Feb; 26(2):154-160. PubMed ID: 29941398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto's Thyroiditis.
    Zhang Q; Liu BJ; Ren WW; He YP; Li XL; Zhao CK; Zhang YF; Yue WW; Zheng JY; Xu HX
    Sci Rep; 2017 Jul; 7(1):4899. PubMed ID: 28687736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating BRAF
    Zhang Z; Zhang X; Yin Y; Zhao S; Wang K; Shang M; Chen B; Wu X
    BMC Cancer; 2022 Apr; 22(1):461. PubMed ID: 35473554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
    Elisei R; Viola D; Torregrossa L; Giannini R; Romei C; Ugolini C; Molinaro E; Agate L; Biagini A; Lupi C; Valerio L; Materazzi G; Miccoli P; Piaggi P; Pinchera A; Vitti P; Basolo F
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.